Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adherence to Oral vs IV Ibandronate in Postmenopausal Osteoporosis
NCT02598453Phase 4Completed
- Sponsor
- Roche
- Start
- Jan 2005
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ibandronate in postmenopausal osteoporosis and osteopenia (2 arms), sponsored by Roche. Primary endpoint: Percentage of participants who have greater than or equal to 75 percent adherence using either monthly oral ibandronate or quarterly intravenous ibandronate at 12 months. Started Jan 2005; status: completed.
02
Drugs
ibandronate
03
Conditions
postmenopausal osteoporosisosteopenia
Beyond the preview
Go deeper on NCT02598453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598453.